Metastatic Triple-Negative Breast Carcinoma Clinical Trials

16 studies are recruiting for metastatic triple-negative breast carcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Atlanta, Georgia 3 Boston, Massachusetts 3 Buffalo, New York 3 New York, New York 3

Studies now recruiting

  1. A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer

    Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with ablation (cryoablation or histotripsy) OR pembrolizumab alone. Participants will be randomly assigned.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
    Locations
    7 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06246968 on ClinicalTrials.gov

  2. Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

    This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has spread from where it first started (primary site) to other places…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    UCHealth University of Colorado Hospital, Aurora, Colorado
    Locations
    30 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT03606967 on ClinicalTrials.gov

  3. Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

    This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the body (advanced). The experimental vaccine is designed target certain prot…

    Stage
    Phase 1
    Ages
    16 and older
    Site
    Mayo Clinic in Florida, Jacksonville, Florida
    Run by
    Mayo Clinic

    See if you can join NCT05269381 on ClinicalTrials.gov

  4. Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

    This phase Ib trial tests the safety and tolerability of ZEN003694 in combination with an immunotherapy drug called pembrolizumab and the usual chemotherapy approach with nab-paclitaxel for the treatment of patients with triple negative-negative breast cancer that has spread to other parts of the b…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Boston Medical Center, Boston, Massachusetts
    Locations
    6 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT05422794 on ClinicalTrials.gov

  5. DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

    The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that has spread to the brain. The name of the study drug used in this research study is: Datopotamab deruxtecan (a type of antibody-drug conjugate)

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Miami Baptist Cancer Institute/, Miami, Florida
    Locations
    3 in total
    Run by
    Nancy Lin, MD

    See if you can join NCT06176261 on ClinicalTrials.gov

  6. Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

    This phase II trial studies the side effects and best dose of ivermectin in combination with balstilimab or pembrolizumab and to see how well they they work in shrinking tumors in patients with triple negative breast cancer that has spread to other places in the body (metastatic). Immunotherapy wit…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Cedars-Sinai Medical Center, Los Angeles, California
    Run by
    Yuan Yuan

    See if you can join NCT05318469 on ClinicalTrials.gov

  7. A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

    This phase II trial studies how well a cancer vaccine called STEMVAC works in combination with chemotherapy in treating patients with PD-L1 negative, triple-negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). STEMVAC is designe…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
    Run by
    University of Washington

    See if you can join NCT07078604 on ClinicalTrials.gov

  8. Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

    This phase IIa trial studies how well dendritic cell vaccines against Her2/Her3 and pembrolizumab work for the treatment of triple negative breast cancer or HER2+ breast cancer or HER+ Breast cancer that has spread to the brain (brain metastasis). Dendritic cell vaccines work by boosting the immune…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Roswell Park Cancer Institute, Buffalo, New York
    Locations
    3 in total
    Run by
    Roswell Park Cancer Institute

    See if you can join NCT04348747 on ClinicalTrials.gov

  9. Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

    This phase I trial tests the safety, side effects, and best dose of pidnarulex in combination with trastuzumab deruxtecan in treating patients with breast cancer and other solid tumors that express varying levels of a protein called HER2 and that has spread from where it first started (primary site…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Dana-Farber Cancer Institute, Boston, Massachusetts
    Locations
    2 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT07137416 on ClinicalTrials.gov

  10. Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

    This phase II trial tests how well evaluating circulating tumor deoxyribonucleic acid (ctDNA) works to guide therapy-change decisions in treating patients with triple-negative breast cancer (TNBC) that has spread from where it first started (primary site) to other places in the body (metastatic). T…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
    Run by
    Vanderbilt-Ingram Cancer Center

    See if you can join NCT05770531 on ClinicalTrials.gov

  11. Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

    This phase II trial tests how well propranolol and pembrolizumab work to cause tumor re-sensitization and therefore treatment in patients with triple negative breast cancer that has not responded to previous checkpoint inhibitor therapy (refractory), cannot be removed by surgery (unresectable) or h…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Emory University Hospital, Atlanta, Georgia
    Locations
    2 in total
    Run by
    Emory University

    See if you can join NCT05741164 on ClinicalTrials.gov

  12. Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

    This phase II trial tests how well tamoxifen and pegylated liposomal doxorubicin works in treating patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or that has spread to nearby tissue or lymph nodes (loca…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Roswell Park Cancer Institute, Buffalo, New York
    Run by
    Roswell Park Cancer Institute

    See if you can join NCT06434064 on ClinicalTrials.gov

  13. High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

    This phase II trial tests how well radiation therapy with pembrolizumab and chemotherapy (paclitaxel or nab-paclitaxel or carboplatin and gemcitabine) works in treating patients with PD-L1 positive triple negative breast cancer that has spread from where it first started (primary site) to other pla…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
    Run by
    Emory University

    See if you can join NCT06492759 on ClinicalTrials.gov

  14. Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

    This phase I trial tests the safety, side effects, and best dose of a personalized vaccine (tumor membrane vesicle or TMV vaccine) by itself and in combination with checkpoint inhibitor (pembrolizumab or ipilimumab) in treating patients with triple negative breast cancer. This vaccine is made by ta…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Grady Health System, Atlanta, Georgia
    Locations
    4 in total
    Run by
    Emory University

    See if you can join NCT06324240 on ClinicalTrials.gov

  15. Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

    Antibody-drug conjugates (ADCs) have demonstrated substantial improvement in progression free survival (PFS) and overall survival (OS) in phase III clinical trials in patients with metastatic triple negative breast cancer (mTNBC) and hormone receptor positive/HER2 negative (HR+/HER2-) metastatic br…

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of California, San Francisco, San Francisco, California
    Run by
    University of California, San Francisco

    See if you can join NCT06774027 on ClinicalTrials.gov

  16. Neratinib in Combination With Ruxolitinib in Patients With mTNBC

    The goal of this clinical trial is to assess the safety and efficacy of combined ruxolitinib and neratinib in patients with chemotherapy-pretreated metastatic triple negative breast cancer. This trial will evaluate one dosing schedule of neratinib in ruxolitinib in patients with metTNBC with locore…

    Stage
    EARLY_Phase 1
    Ages
    18 and older
    Site
    Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas, Texas
    Run by
    Baylor Research Institute

    See if you can join NCT06008275 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.